BR0309778A - Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2b - Google Patents
Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2bInfo
- Publication number
- BR0309778A BR0309778A BR0309778-1A BR0309778A BR0309778A BR 0309778 A BR0309778 A BR 0309778A BR 0309778 A BR0309778 A BR 0309778A BR 0309778 A BR0309778 A BR 0309778A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- dihydroquinolin
- compounds
- nr2b receptor
- receptor antagonists
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical class C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 2
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 2
- ZTOSZJPNPROTBL-FQEVSTJZSA-N 6-[(1r)-2-[4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl]-1-hydroxyethyl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=C2CCC(=O)NC2=CC=1)N(CC1)CCC1(O)C1=CC=CC(F)=C1 ZTOSZJPNPROTBL-FQEVSTJZSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37593902P | 2002-04-26 | 2002-04-26 | |
| PCT/IB2003/001556 WO2003091241A1 (en) | 2002-04-26 | 2003-04-15 | 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309778A true BR0309778A (pt) | 2005-03-08 |
Family
ID=29270728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309778-1A BR0309778A (pt) | 2002-04-26 | 2003-04-15 | Compostos 3,4-di-hidroquinolin-2(1h)-ona como antagonistas do receptor nr2b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6713490B2 (enExample) |
| EP (1) | EP1499606B8 (enExample) |
| JP (1) | JP2005524696A (enExample) |
| AR (1) | AR039663A1 (enExample) |
| AT (1) | ATE325117T1 (enExample) |
| AU (1) | AU2003219398A1 (enExample) |
| BR (1) | BR0309778A (enExample) |
| CA (1) | CA2483636A1 (enExample) |
| DE (1) | DE60305026T2 (enExample) |
| ES (1) | ES2258716T3 (enExample) |
| MX (1) | MXPA04010549A (enExample) |
| PA (1) | PA8572601A1 (enExample) |
| TW (1) | TW200406402A (enExample) |
| UY (1) | UY27776A1 (enExample) |
| WO (1) | WO2003091241A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| MXPA06003748A (es) * | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| EP1736474A4 (en) * | 2004-04-07 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | piperidine |
| HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
| US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| US20120077883A1 (en) * | 2009-03-31 | 2012-03-29 | De Barros Coelho Claudia Couto | Treatment of tinnitus and associated auditory dysfunctions |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| EP2621475A1 (en) | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| RU2068414C1 (ru) | 1990-05-10 | 1996-10-27 | Пфайзер Инк. | Производные индолона в виде рацемата или оптически активного изомера или их фармацевтически приемлемые аддитивные соли кислоты и кетопроизводные индолона |
| EP0666854B1 (en) | 1992-10-30 | 1997-03-26 | Pfizer Inc. | Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds |
| US6407235B1 (en) | 2000-08-21 | 2002-06-18 | Hoffmann-La Roche Inc. | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 EP EP03715209A patent/EP1499606B8/en not_active Expired - Lifetime
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en not_active Ceased
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2258716T3 (es) | 2006-09-01 |
| EP1499606B8 (en) | 2006-08-30 |
| US20030216430A1 (en) | 2003-11-20 |
| MXPA04010549A (es) | 2005-02-17 |
| DE60305026T2 (de) | 2006-10-12 |
| JP2005524696A (ja) | 2005-08-18 |
| DE60305026D1 (de) | 2006-06-08 |
| EP1499606A1 (en) | 2005-01-26 |
| US6713490B2 (en) | 2004-03-30 |
| TW200406402A (en) | 2004-05-01 |
| CA2483636A1 (en) | 2003-11-06 |
| EP1499606B1 (en) | 2006-05-03 |
| PA8572601A1 (es) | 2004-12-16 |
| AR039663A1 (es) | 2005-03-02 |
| UY27776A1 (es) | 2003-11-28 |
| WO2003091241A1 (en) | 2003-11-06 |
| ATE325117T1 (de) | 2006-06-15 |
| AU2003219398A1 (en) | 2003-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5656874B2 (ja) | Ｐｄｅ９阻害剤として使用されるアミノヘテロ環化合物 | |
| CA2629461C (en) | Substituted quinolones and methods of use | |
| TWI659945B (zh) | 作爲鈉通道調節劑之醯胺 | |
| EP2316831B1 (en) | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | |
| TWI500616B (zh) | 新穎之雙環吡啶酮 | |
| MX2010003346A (es) | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. | |
| WO2004014850A3 (en) | Substituted aminopyrimidines as neurokinin antagonists | |
| NZ600674A (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| BRPI0408988A (pt) | composto de piperidinilamino-tieno[2,3-d]pirimidina | |
| SK185399A3 (en) | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION ANDì (54) ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | |
| JP6661605B2 (ja) | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 | |
| BRPI0509761B8 (pt) | compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação | |
| BR0312572A (pt) | Derivados de azabiciclo como antagonistas de receptores muscarìnicos | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| CA2485753A1 (en) | Benzimidazole derivatives | |
| EA031087B1 (ru) | 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| AU2017347549A1 (en) | Therapeutic compounds and methods of use thereof | |
| AR039663A1 (es) | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b | |
| DE602004005502D1 (de) | Comt-inhibitoren | |
| IL179599A0 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| JP6987746B2 (ja) | 治療用化合物及びその使用方法 | |
| BRPI0409302A (pt) | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos | |
| SG158924A1 (en) | Modulators of chemokine receptor activity, crystalline forms and process | |
| JPWO2005100341A1 (ja) | ２−アミノピリミジン誘導体 | |
| AR037711A1 (es) | Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |